Britecyte announced a $1,000,000 Clinical Program Grant from the Maryland Stem Cell Research Fund (MSCRF) supporting novel adipose tissue allograft therapy for osteoarthritis.
The award advances Britecyte’s clinical program evaluating BRC-OA, a human adipose allograft, for the treatment of knee osteoarthritis—a serious and debilitating disease affecting tens of millions of adults.